IGF2BP3 and central nervous system cancer: Indeed, our study demonstrated that BET inhibitors (JQ1, I-BET151) time-dependently inhibited the expression of both IGF2BP3 and CSF3 in glioma cells (Supplementary Fig. 6a–f).